Jones began purchasing gritstone; Cancer, COVID-19 vaccine citations (GRTS)


Jones began purchasing gritstone;  Cancer, COVID-19 vaccine citations (GRTS)

Simen Stromme/iStock via Getty Images

Jones Research has initiated coverage of Gritstone Bio (Nasdaq: GRTS) with a buy rating and price target of $10.

The research group said it sees Gritstone as a “highly underappreciated story” with its vaccine candidates for SARS-CoV-2 and microsatellite-stable colorectal cancer, or MSS-CRC.

Leave a Comment

“The Untold Story: Yung Miami’s Response to Jimmy Butler’s Advances During an NBA Playoff Game” “Unveiling the Secrets: 15 Astonishing Facts About the PGA Championship”